Publication | Closed Access

Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors

Novel 2-Arylbenzimidazole/2-thiopyrimidinesMedicinal ChemistryVegfr-2 Kinases InhibitorsMedicinePharmacological AgentPharmacotherapyAnti-cancer AgentDrug DevelopmentPharmacologyRadiation OncologyPharmaceutical ChemistryAnticancer ActivityDrug Discovery